Karissa is a combined hormonal contraceptive primarily utilized for symptomatic support for preventing pregnancy, generally supporting fertility management for women in their reproductive years. Its classification as a combined oral contraceptive (COC) indicates its main use is to prevent conception. Beyond this core function, the medication provides therapeutic benefits that address specific symptom domains often linked to hormonal activity.

In clinical scenarios, the preparation is commonly applied to manage symptoms related to the menstrual cycle, including heavy bleeding (menorrhagia), severe pain (dysmenorrhea), and manifestations of premenstrual dysphoric disorder (PMDD). It is also relevant for establishing predictable cycle patterns, and for the management of external symptoms such as moderate to severe hormonal acne vulgaris and hirsutism (excessive hair growth).

“The medication is generally used in contexts where patients require symptomatic support for fertility control alongside supportive management for recurrent cycle-related discomfort.”

This dual functionality means that in addition to contraception, the medication contributes to easing the overall symptom load and supports a more manageable experience during symptomatic periods, which may assist with improving day-to-day comfort.

Quick Fact: Relief for Pain and Irregularity

Karissa may assist in reducing the severity of cycle irregularity and provides symptomatic support for symptoms related to menstrual pain.

Regulatory References

1. NIH MedlinePlus overview of COCs

Karissa is officially designated for use in females of reproductive potential who seek systemic hormonal contraception. Eligibility is strictly determined by ruling out specific health conditions classified as contraindications in official regulatory documents.

Category	Official Regulatory Status
Populations for whom use is contraindicated	Females with a high risk of arterial or venous thrombotic diseases, including a history of blood clots (DVT, PE, stroke) or inherited clotting disorders. Also contraindicated with known or suspected pregnancy, breast cancer, liver tumors/severe liver disease, and undiagnosed abnormal genital bleeding.
Age and Condition Restrictions	Contraindicated in females over age 35 who smoke, or those with migraine headaches with aura, or uncontrolled hypertension. It is not indicated after menopause and should not be used before the start of menstruation (menarche).
Pregnancy and Lactation Status	Pregnancy is a contraindication. Use is not recommended for women who are breastfeeding.
Eligibility-related Restrictions	Use must be stopped at least 4 weeks before and through 2 weeks after major surgery or other periods of prolonged immobilization.

The regulatory profile defines eligibility by prioritizing the avoidance of severe thrombotic risk and hormone-sensitive conditions. Use is permitted only for those without the specified exclusionary criteria.

The official regulatory profile for Karissa is defined by interactions that alter the systemic exposure of either the contraceptive hormones or a co-administered medicine. This framework establishes strict constraints, including formal prohibitions and the risk of reduced contraceptive effectiveness.

Interaction Type	Interacting Substances	Official Outcome
Strictly Contraindicated	Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir (Anti-HCV combinations)	Co-administration is prohibited due to the documented risk of significant elevation of liver enzymes (ALT).
Reduced Exposure (Efficacy)	Rifampin, Phenytoin, Carbamazepine, Phenobarbital, St. John's Wort (Herbal)	These substances accelerate the breakdown and clearance of Karissa's hormones through hepatic enzyme induction, resulting in reduced plasma concentrations and loss of contraceptive effectiveness.
Increased Exposure of Other Drugs	Tizanidine	Karissa can inhibit the metabolism of Tizanidine, which leads to a substantial increase (up to 3.9-fold) in Tizanidine's systemic exposure.
Food & Other Products	Grapefruit Juice	May increase the plasma concentrations of the hormonal components.

The most common clinically relevant pattern involves enzyme-inducing medicines, where the potential for reduced hormonal exposure requires consideration of alternative contraception. The use of the oral contraceptive may also affect the levels of certain co-administered medicinal products, such as Etoricoxib, which may have increased plasma levels. These documented patterns of metabolic interference and strict prohibitions define the official interaction-related constraints.

How Karissa Works

The mechanism of action for Karissa is centered on the central nervous system (CNS), involving both the parent compound and its active metabolite. The primary molecular interaction occurs at the GABAA receptor complex, where the drug and its metabolite engage in positive allosteric modulation. This enhances inhibitory GABAergic signaling, resulting in increased neuronal hyperpolarization and reduced overall CNS excitability.

Simultaneously, the molecule selectively modulates interneurons located within the spinal cord and descending reticular formation. This action decreases the efficacy of signal transmission across polysynaptic reflex arcs, which constitute key pathways governing muscle tone and reflex activity. The parent compound is metabolized into an active compound (meprobamate) that continues to exert CNS effects through GABA modulation. This contributes to prolonged modulation of central nervous system pathways, which shapes the resulting physiological consequences on motor function.

Administration Protocol: Daily Cyclic Use

Karissa is an oral medication administered exclusively via the oral route as a film-coated tablet. The medicine contains a fixed-dose combination of 75 mcg Gestodene and 30 mcg Ethinyl Estradiol, intended for standardized daily use.

The official administration protocol is structured around a mandatory 28-day cycle. This regimen involves taking one active tablet daily for 21 consecutive days, which must be followed by a 7-day period during which either inactive (placebo) tablets are taken or no tablets are taken at all. This cyclic approach dictates the continuous pattern of use, and the tablets should be swallowed whole with some liquid.

For the medicine to be used correctly, it is a procedural requirement that each tablet be taken at approximately the same time every day, irrespective of meals, as a consistent time maintains the steady-state drug levels. The tablets must be taken in the order directed on the blister pack to maintain the correct sequencing of the hormonal cycle.

Official administration guidelines advise that a non-hormonal barrier method (e.g., condom) should be utilized for the first seven days of the initial cycle, particularly if the tablet-taking is started later than the first day of the menstrual period. The regimen is standardized for women of reproductive potential, including post-menarche adolescents, with the specific dosing based on the standard adult use protocol. Specific, time-sensitive instructions are provided within the labeling for managing missed active tablets.

Research Evidence / Overview of Studies

Core Research Focus

Studies were conducted to investigate the drug's intended biological target, a protein involved in the inflammatory cascade associated with Rheumatoid Arthritis (RA). This mechanism of action was the objective of several Phase II and Phase III clinical trials, primarily involving adult participants.

Primary Efficacy Data

Controlled trials examined the drug’s use in participants with moderate to severe RA who had not responded adequately to prior disease-modifying anti-rheumatic drugs (DMARDs). The research primarily assessed changes in disease activity using standardized measurement criteria, such as the American College of Rheumatology (ACR) response scores (ACR20, ACR50, and ACR70), and measures of joint tenderness and swelling.

• Observed Changes: The primary studies observed changes in disease activity over 12 months. This observation was focused on participants who received the highest tested dose compared to those receiving placebo.
• Secondary Endpoints: Research also explored outcomes related to patient-reported symptoms, including measures of pain, morning stiffness, and fatigue.

Combination Therapy Findings

Research included randomized, double-blind trials that compared the drug to placebo and evaluated its use when combined with methotrexate. These studies aimed to determine whether the combination treatment met the established clinical endpoints in reducing signs and symptoms of RA.

Safety and Adverse Events

Safety assessments conducted during the clinical development phase considered specific patient populations, such as those with pre-existing kidney or liver problems. The most commonly reported adverse events included infections (such as upper respiratory tract infections) and changes in specific laboratory markers, including liver enzyme levels. Immunogenicity was monitored in the trials, with neutralizing antibodies detected in a small percentage of participants; the clinical relevance of these findings was not fully established by the studies.

Key Studies & References Kevzara (Sarilumab): A Novel IL-6 Receptor Antagonist for Rheumatoid Arthritis (Pivotal Trial Review)

Common questions about Karissa (FAQ)

Q: How quickly does Karissa start to work?

A: According to official product information, full contraceptive protection is typically achieved after taking seven consecutive days of active tablets. If the regimen is started later than the first day of the menstrual cycle, regulatory guidance indicates that the use of an additional non-hormonal barrier method is recommended during those first seven days.

Q: What happens if I accidentally miss a dose of Karissa?

A: Instructions for managing a missed dose depend on how many pills were missed and the week of the cycle. Missing an active tablet by more than 12 hours may reduce contraceptive protection, according to regulatory guidelines. Specific, time-sensitive instructions are provided in the labeling for consultation, and these instructions may include taking the missed pill immediately and using a back-up birth control method.

Q: Are there any long-term effects of taking Karissa?

A: Official regulatory documents confirm that long-term use is associated with an increased risk of serious vascular events, such as venous thromboembolic events (blood clots). There is also a documented association with certain neoplasms, which include benign liver tumors, which are important safety warnings regarding long-term exposure.

Q: What research evidence supports the use of Karissa?

A: The efficacy of Karissa is supported by clinical trials, including non-comparative Phase 3 studies. These trials investigated the specific safety and effectiveness profile of the active hormonal combination for the prevention of pregnancy, as described in the official product labeling.

Q: What is the maximum amount of time someone has been studied on Karissa?

A: According to summaries of the clinical development program, safety and efficacy trials often include data gathered from women who used the tablets for at least one year. These trials were used to establish the drug's safety profile over that duration.

Q: How is the safety profile of Karissa described in regulatory documents?

A: Regulatory documents describe the safety profile as including commonly reported, non-serious adverse reactions, such as headaches and nausea. Critically, the official labeling includes a well-established warning regarding an increased risk of serious vascular events (thromboembolism), which is noted to be highest during the first year of use.

Q: What is Karissa used for besides the main condition?

A: Although Karissa is officially approved and labeled for pregnancy prevention, the hormonal combination is associated with additional non-contraceptive benefits. These benefits, noted in official sources, include improving acne, reducing menstrual pain (dysmenorrhea), and contributing to the regulation of irregular periods.

Q: Is it normal to feel tired when starting Karissa?

A: Fatigue or a lack of energy has been reported as an adverse reaction for similar hormonal contraceptive combinations in official medical sources. These effects are classified as common in some product documentation.

Q: Do I need to change my diet while taking Karissa?

A: No general dietary changes are mandated in the official product labeling for Karissa. However, the regulatory documents specifically note that consuming grapefruit juice may increase the plasma concentration of the hormonal components.

Q: Does Karissa affect blood pressure?

A: According to the official product information, the use of Karissa is associated with an increase in blood pressure. Due to this effect, the medication is contraindicated (prohibited from use) for individuals with pre-existing or uncontrolled hypertension.

Q: Can Karissa make you feel anxious or depressed?

A: Regulatory documents list mood changes, including a worsening of mood and feelings of depression, as reported side effects. These reactions are associated with the use of the hormonal combination.

Q: Is Karissa a controlled substance?

A: Karissa is a combined hormonal contraceptive and is not classified as a controlled substance under the regulatory frameworks of major jurisdictions, such as the US Controlled Substances Act.

Q: Is it safe to drink alcohol in small amounts while on Karissa?

A: Official product information suggests that caution should be exercised regarding alcohol consumption while using Karissa. Some data indicates a potential, typically minor, interaction may occur.

Q: How often do I need to see my doctor while taking Karissa?

A: Regulatory guidance suggests that doctors may recommend regular medical monitoring while on the medication. This monitoring can include check-ups for blood pressure, blood tests, and cervical smear tests.

Q: What is the experience of switching from another medicine to Karissa?

A: Official administration instructions specify that when switching from another combined oral contraceptive, the transition should occur on the day a new pack of the previous medication would have normally been started.

Q: Why do some people experience headaches with Karissa?

A: Headaches, including migraines, are listed as common adverse reactions in the official product labeling. These effects are thought to be related to the hormonal changes that occur when beginning or continuing a combined oral contraceptive regimen.

Q: Does Karissa have a generic version available?

A: Yes, the combination of active ingredients in Karissa (Gestodene and Ethinyl Estradiol) is widely available in generic formulations. These generic versions are listed under various names in regulatory registries.

Q: What should I do if the side effects of Karissa are mild?

A: Mild side effects, such as nausea and breakthrough bleeding, are commonly reported, especially when starting the medication. Official information indicates that these effects often tend to diminish or resolve spontaneously within the first few months of use.

Q: Is Karissa addictive?

A: Regulatory documentation for Karissa confirms that there is no indication that the medication is addictive or possesses abuse potential.

Q: Are there any specific minerals or vitamins that interact with Karissa?

A: Regulatory product information notes potential interactions with multivitamin and mineral supplements. Official regulatory interaction information should be consulted regarding the hormonal components.

Q: Is Karissa considered a high-risk medication?

A: Regulatory documents include a critical warning regarding the increased risk of serious vascular events (blood clots) associated with use. This necessitates strict contraindications and patient selection criteria, particularly due to the heightened risk during the first year of use.

Q: Can Karissa affect sleep patterns?

A: Difficulty in sleeping or changes to sleep patterns have been reported as an adverse reaction for similar hormonal combinations in authoritative medical sources.

Q: Is it true that Karissa can cause problems with vision?

A: Sudden changes in vision or the occurrence of severe headaches/migraines with aura are listed in official labeling as potential symptoms of serious vascular events. These symptoms are listed in the official labeling as requiring immediate medical consultation.

Q: Can I take ibuprofen or acetaminophen while using Karissa?

A: Regulatory interaction databases note that acetaminophen (Paracetamol) has minor documented interactions with the active hormones. Concurrent use with ibuprofen is generally not classified as a major drug interaction.

Q: Are there any restrictions on driving while taking Karissa?

A: Official safety advice for Karissa indicates that the medication does not typically affect a user's ability to drive.

Q: Can I stop taking Karissa suddenly?

A: Official product labeling advises that stopping the medication may result in a rapid return of fertility. Information regarding the risks and benefits associated with use is included in the labeling for consultation when considering discontinuation.

Q: Is Karissa generally well-tolerated?

A: While common side effects, such as nausea and breakthrough bleeding, are frequently reported, these typically resolve after the first few months of use. This suggests a generally well-tolerated profile once the body adjusts to the medication.

Q: Can Karissa cause skin rash or itching?

A: Skin rash, itching, and hives have been reported in official documents as potential symptoms of allergic reactions associated with the medication.

Q: How do doctors monitor the effects of Karissa?

A: Regulatory advice suggests that doctors may recommend regular check-ups to monitor the effects of the medication. This monitoring can include blood pressure checks, blood tests, and cervical smear tests.

Q: Is Karissa only available by prescription?

A: Yes, Karissa is classified as a combined hormonal contraceptive, and in all major regulatory jurisdictions, it is designated as a medication that requires a prescription.

Q: Are the benefits of Karissa supported by long-term studies?

A: Yes, clinical trials conducted for the hormonal combination have followed users for a minimum of one year. This data gathering was used to support the long-term safety and efficacy of the medication.

How to Store and Dispose of Karissa

Karissa (desogestrel/ethinyl estradiol) tablets must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), with permitted brief excursions from 15 C to 30 C.

Storage Requirements

The medication must be kept in its original container and maintained away from excess heat and moisture; therefore, storage in the bathroom is prohibited. The container must be kept tightly closed to protect the product. It is a mandatory requirement to keep Karissa out of the reach of children and pets at all times.

Disposal

Unused or expired Karissa must be disposed of according to local guidelines, usually by consulting a pharmacist for a take-back program. If no program is available, the FDA advises mixing the medicine with an unappealing substance, sealing it in a container, and placing it in household trash.